Movement Disorder Management — MDS 2026
Overview
Movement Disorder Management at the 2026 International Congress of the Movement Disorder Society (MDS) represents a comprehensive synthesis of contemporary clinical practices, emerging therapeutic strategies, and mechanistic insights into progressive neurological conditions affecting motor control. The MDS 2026 Congress in Seoul provided a platform for dissemination of evidence-based approaches to managing Parkinson's disease (PD), essential tremor (ET), dystonia, Huntington's disease (HD), and related movement disorders. This gathering highlighted the evolution from symptomatic treatment paradigms toward disease-modifying therapies and precision medicine approaches, reflecting the field's advancing understanding of underlying pathophysiology and individualized patient care optimization.
Function/Biology
Movement disorders encompass a diverse spectrum of neurological conditions characterized by abnormalities in motor control, resulting from dysfunction within basal ganglia circuits, cerebellar systems, and motor cortical networks. Normal motor function depends on coordinated activity between the direct (facilitatory) and indirect (inhibitory) motor pathways within the basal ganglia, balanced dopaminergic neurotransmission, and proper integration of sensorimotor information. Movement disorders arise from disruption of these circuits through neuronal loss, protein aggregation, mitochondrial dysfunction, or altered neurotransmitter synthesis and signaling. The biological substrates vary substantially across diagnostic categories: PD involves primarily dopaminergic substantia nigra degeneration; ET reflects cerebellar and olivary pathway dysfunction; dystonia involves abnormal motor circuit plasticity and GABAergic inhibition deficits; and HD results from polyglutamine-induced neuronal toxicity affecting striatal medium spiny neurons.
Role in Neurodegeneration
Movement disorders represent major categories within the neurodegeneration spectrum, collectively affecting millions globally. Parkinson's disease, the most common movement disorder, involves progressive loss of dopaminergic neurons and accumulation of alpha-synuclein (SNCA) protein aggregates, leading to characteristic resting tremor, rigidity, bradykinesia, and postural instability. Huntington's disease results from polyglutamine (CAG) repeat expansion in the HTT gene, causing transcriptional dysregulation and selective striatal neurodegeneration. Essential tremor, though less understood mechanistically, involves cerebellar and thalamic circuitry dysfunction. ALS-associated movement abnormalities stem from motor neuron degeneration through TDP-43 and FUS protein pathology. These conditions share common pathogenic mechanisms including proteostasis impairment, mitochondrial dysfunction, neuroinflammation, and excitotoxicity, making them targets for convergent therapeutic intervention.
Molecular Mechanisms
Contemporary movement disorder management increasingly targets specific molecular pathways underlying disease progression. For Parkinson's disease, therapies address dopaminergic deficiency through levodopa replacement, monoamine oxidase inhibitors (MAOI), catechol-O-methyltransferase (COMT) inhibitors, and dopamine agonists targeting D1 and D2 receptors. Emerging disease-modifying approaches target alpha-synuclein pathology through immunotherapy, inhibition of protein-protein interactions, and enhancement of proteostatic pathways via ubiquitin-proteasome system and autophagy-lysosomal pathway activation. Huntington's disease management now includes huntingtin-lowering approaches using antisense oligonucleotides (ASOs) targeting HTT transcripts and small-molecule inhibitors of mutant huntingtin protein aggregation. GABAergic circuit restoration strategies, particularly enhancing GABA synthesis and receptor function, provide therapeutic targets across multiple movement disorders. Deep brain stimulation (DBS) modulates circuit activity at the systems level, with neurocircuit mapping and closed-loop stimulation representing advancing technological platforms.
Clinical/Research Significance
The MDS 2026 Congress emphasized that personalized medicine approaches, incorporating genetic stratification, biomarker profiling, and advanced neuroimaging, improve therapeutic selection and patient outcomes. Early diagnosis initiatives utilizing objective motor assessments, neuroimaging markers (striatal dopamine transporter imaging in PD, brain iron quantification), and circulating biomarkers (phosphorylated alpha-synuclein, neurofilament light chain) enable intervention during less advanced disease stages. Long-term outcome data from disease-modifying trials and real-world effectiveness studies inform clinical decision-making regarding treatment initiation and sequencing.
Closely related research domains include alpha-synuclein pathology and synucleinopathies, dopaminergic system dysfunction, basal ganglia circuitry, proteostasis and protein aggregation mechanisms, neuroinflammatory processes, mitochondrial dysfunction in neurodegeneration, deep brain stimulation technology, motor rehabilitation and physical therapy, genetic counseling in Huntington's disease, and biomarker development for disease progression monitoring.